AstraZeneca's CD19×CD3 bispecific therapy for leukemia has been approved for clinical trials in China.

AstraZeneca has been approved to conduct clinical trials for treating leukemia in China. The company's new drug AZD0486 is intended for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). AZD0486 is a bispecific T-cell engager protein targeting CD19×CD3, which can guide T cells to tumor cells and kill them. Previously, AstraZeneca acquired TeneoTwo for approximately $1.27 billion, further diversifying its hematology pipeline. AstraZeneca is currently conducting clinical studies on AZD0486 in the United States to evaluate its safety and efficacy in the treatment of B-ALL and B-cell non-Hodgkin's lymphoma (B-NHL).